Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA Durability: Nemolizumab Withdrawal in Prurigo Nodularis
NCT05052983Phase 3Completed
- Sponsor
- Galderma
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of nemolizumab in prurigo nodularis (PN), sponsored by Galderma. Started Jan 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT05052983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052983.